FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
KYMR Financial Statements
Year
2024
2023
2022
2021
Total Revenue
47.07M
78.59M
46.83M
72.83M
Cost of Revenue
0
189.08M
2.98M
2.4M
Gross Profit
47.07M
-110.49M
43.85M
70.44M
Operating Expenses
308.71M
244.12M
208.08M
173.36M
Research and Development
240.25M
189.08M
164.25M
137.02M
Selling, General & Administrative Expenses
63.53M
55.04M
43.83M
36.34M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
63.53M
55.04M
43.83M
36.34M
Other Expenses
4.92M
0
0
0
Operating Income
-261.63M
-165.53M
-161.26M
-100.53M
Total Other Income/Expenses Net
37.78M
18.57M
6.45M
313k
Income Before Tax
-223.86M
-146.96M
-154.81M
-100.22M
Income Tax
0
0
-2.98M
-2.22M
Net Income
-223.86M
-146.96M
-151.83M
-98M
Basic EPS
-2.98
-2.52
-2.82
-2.04
EPS Diluted
-2.98
-2.52
-2.82
-2.04
Basic Average Shares
75.04M
58.37M
53.93M
47.99M
Diluted Average Shares
75.04M
58.37M
53.93M
47.99M
EBITDA
-216.24M
-143.2M
-151.66M
-97.64M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-530.75M
-383.79M
-228.98M
-128.76M
Net Income
-223.86M
-146.96M
-151.83M
-98M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-754.61M
-530.75M
-383.79M
-228.98M
Other Distributions
-223.86M
-146.96M
-154.81M
-100.22M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
97.86M
101.08M
13.33M
11.88M
Annual Depreciation
7.37M
3.56M
2.98M
2.4M
Capital Expenditure
-12.84M
-34.48M
-2.84M
-1.6M
Net PPE
103.33M
131.99M
13.19M
11.08M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
